Abstract:Ethnopharmacological relevance: Extracts from Ginkgo biloba L. leaves confer their therapeutic effects through the synergistic actions of flavonoid and terpenoid components, but some non-flavonoid and non-terpenoid components also exist in this extract. In the study of this paper, an investigation was carried out to compare the pharmacokinetic parameters of fourteen compounds to clarify the influences of non-flavonoid and non-terpenoid fraction (WEF) on the pharmacokinetics profile of the flavonoid fraction (FF) and the terpene lactone fraction (TLF) from Ginkgo biloba extracts. Materials and methods: A selective and sensitive UPLC-MS/MS method was established to determine the plasma concentrations of the fourteen compounds to compare the pharmacokinetic parameters after orally administration of FF, TLF, FF-WEF, FF-TLF, TLF-WEF and FF-TLF-WEF with approximately the same dose. At different time points, the concentration of rutin (1), isoquercitrin (2), quercetin 3-O-[4-O-(-β-D-glucosyl)-α-L-rhamnoside] (3), ginkgolide C (4), bilobalide (5), quercitrin (6), ginkgolide B (7), ginkgolide A (8), luteolin (9), quercetin (10), apigenin (11), kaempferol (12), isorhamnetin (13), genkwanin (14) in rat plasma were determined and main pharmacokinetic parameters including T1/2, Tmax, Cmax and AUC were calculated using the DAS 3.2 software package. The statistical analysis was performed using the Student׳s t-test with P<0.05 as the level of significance. Results: FF and WEF had no effect on the pharmacokinetic behaviors and parameters of the four terpene lactones, but the pharmacokinetic profiles and parameters of flavonoids changed while co-administered with non-flavonoid components. It was found that Cmax and AUC of six flavonoid aglycones in group FF-WEF, FF-TLF and FF-TLF-WEF had varying degrees of reduction in comparison with group FF, especially in group FF-TLF-WEF. On the contrary, the values of Cmax, Tmax and AUC of four flavonoid glycosides in group FF-TLF-WEF were significantly increased compared with those in group FF. Conclusions: These results indicate that non-flavonoid components in Ginkgo biloba extracts could increase the absorption and improve the bioavailability of flavonoid glycosides but decrease the absorption and reduce the bioavailability of flavonoid aglycones.

The characterisation of the in vitro metabolism and transport of 6-hydroxykynurenic acid, an important constituent of Ginkgo biloba extracts

Pharmacokinetics and Brain Distribution Studies of 6-Hydroxykynurenic Acid and Its Structural Modified Compounds.

[Ginkgo Flavones in in Vitro Metabolism and Its Clinical Application].

Improved Metabolites of Pharmaceutical Ingredient Grade Ginkgo Biloba and the Correlated Proteomics Analysis

The Metabolism and Hepatotoxicity of Ginkgolic Acid (17:1) in Vitro

Interactions of pharmacokinetic profile of different parts from Ginkgo biloba extract in rats

Discovery and Characterization of the Key Constituents in Ginkgo biloba Leaf Extract With Potent Inhibitory Effects on Human UDP-Glucuronosyltransferase 1A1

Influence of Organic Anion Transporter 1/3 on the Pharmacokinetics and Renal Excretion of Ginkgolides and Bilobalide.

Characterization of human UDP-glucuronosyltransferases responsible for glucuronidation and inhibition of norbakuchinic acid, a primary metabolite of hepatotoxicity and nephrotoxicity component bakuchiol in Psoralea corylifolia L.

The Potential Drug-Drug Interactions of Ginkgolide B Mediated by Renal Transporters

Systemic and cerebral exposure to and pharmacokinetics of flavonols and terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different routes of administration.

[Glucuronidation and in Vitro Interaction of Ginkgo Flavonoids with Other Drugs].

Pharmacokinetic studies of ginkgolide K in rat plasma and tissues after intravenous administration using ultra-high performance liquid chromatography-tandem mass spectrometry

Target Profiling of Flavonol Glycosides in the Extract of Ginkgo Biloba Leaf and Their Pharmacokinetics in Rat Plasma by Ultra-High-performance Liquid Chromatography with Tandem Mass Spectrometry

Development and Validation of a Sensitive LC-MS/MS Method for the Determination of 6-Hydroxykynurenic Acid in Rat Plasma and Its Application to Pharmacokinetics Study.

Ginkgo biloba and Its Constituent 6-hydroxykynurenic-acid as well as Its Proanthocyanidins Exert Neurorestorative Effects against Cerebral Ischemia

Structural Elucidation of Metabolites of Ginkgolic Acid in Rat Liver Microsomes by Ultra-Performance Liquid Chromatography/Electrospray Ionization Tandem Mass Spectrometry and Hydrogen/Deuterium Exchange

Identification of Ginkgolide B Metabolites in Urine and Rat Liver Cytochrome P450 Enzymes Responsible for Their Formation in Vitro.

Human Pharmacokinetics of Ginkgo Terpene Lactones and Impact of Carboxylation in Blood on Their Platelet-Activating Factor Antagonistic Activity

The Biology and Biochemistry of Kynurenic Acid, a Potential Nutraceutical with Multiple Biological Effects

Characterization of Metabolism and in Vitro Permeability Study of Notoginsenoside R1 from Radix Notoginseng